

**PRIOR AUTHORIZATION REQUEST FORM  
PROLIA®, XGEVA®**

**For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 801-213-1547.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have medical pharmacy prior authorization questions, please call for assistance: Individual Exchange: 833-981-0214, Commercial Groups: 833-981-0213, MHC: 844-262-1560

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:	HCPCS Code:	

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Product being requested:**  Prolia® (denosumab),  XGEVA® (denosumab)

Dosing/Frequency: \_\_\_\_\_

**If the request is for reauthorization, proceed to reauthorization section**

Questions	Yes	No	Comments/Notes
<b>PROLIA® FOR OSTEOPOROSIS</b>			
1. Has the member been diagnosed with osteoporosis?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Does the member have a documented baseline bone mineral density (BMD) T-score of $\leq -2.5$ by DEXA scan?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member had a 24-month trial and failure to a bisphosphonate?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>PROLIA® FOR BONE LOSS SECONDARY TO AROMATASE INHIBITORS</b>			
1. Has the member been diagnosed with breast cancer and is currently taking an aromatase inhibitor?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Does the member have a documented baseline bone mineral density (BMD) T-score of $< -1.0$ by DEXA scan?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member had a 24-month trial and failure with a bisphosphonate?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>PROLIA® FOR HORMONE- SENSITIVE PROSTATE CANCER</b>			
1. Has the member been diagnosed with Hormone-Sensitive Prostate Cancer and currently taking androgen deprivation therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

2. Does the member have a FRAX score of 10-year probability of hip fracture >3% or a 10-year probability of major osteoporosis-related fracture of >20%?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member had a 24-month trial and failure to a bisphosphonate?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>XGEVA®</b>			
1. Has the member been diagnosed with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Does the member have a diagnosis of metastatic bone disease from solid tumor and has had a trial and failure to a bisphosphonate?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Has the member been diagnosed with hypercalcemia of malignancy refractory to bisphosphonate therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Has the member had a trial and failure of an intravenous bisphosphonate, unless contraindicated?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>REAUTHORIZATION</b>			
1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Has the therapy shown to be effective with an improvement or stabilization in condition?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does the member have a continued medical need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician's Signature:			

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-M006  
 Origination Date: 08/07/2017  
 Reviewed/Revised Date: 09/13/2023  
 Next Review Date: 09/13/2024  
 Current Effective Date: 10/01/2023

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.